|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPIE |
Gene summary for PPIE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPIE | Gene ID | 10450 |
| Gene name | peptidylprolyl isomerase E | |
| Gene Alias | CYP-33 | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9UNP9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10450 | PPIE | LZE4T | Human | Esophagus | ESCC | 1.92e-11 | 2.62e-01 | 0.0811 |
| 10450 | PPIE | LZE7T | Human | Esophagus | ESCC | 2.61e-13 | 7.96e-01 | 0.0667 |
| 10450 | PPIE | LZE8T | Human | Esophagus | ESCC | 1.45e-05 | 3.06e-01 | 0.067 |
| 10450 | PPIE | LZE22T | Human | Esophagus | ESCC | 9.01e-04 | 4.44e-01 | 0.068 |
| 10450 | PPIE | LZE24T | Human | Esophagus | ESCC | 2.10e-10 | 2.37e-01 | 0.0596 |
| 10450 | PPIE | LZE6T | Human | Esophagus | ESCC | 2.21e-05 | 3.06e-01 | 0.0845 |
| 10450 | PPIE | P1T-E | Human | Esophagus | ESCC | 3.97e-04 | 3.45e-01 | 0.0875 |
| 10450 | PPIE | P2T-E | Human | Esophagus | ESCC | 1.53e-36 | 7.40e-01 | 0.1177 |
| 10450 | PPIE | P4T-E | Human | Esophagus | ESCC | 4.84e-28 | 5.31e-01 | 0.1323 |
| 10450 | PPIE | P5T-E | Human | Esophagus | ESCC | 9.66e-18 | 4.63e-01 | 0.1327 |
| 10450 | PPIE | P8T-E | Human | Esophagus | ESCC | 1.80e-19 | 4.22e-01 | 0.0889 |
| 10450 | PPIE | P9T-E | Human | Esophagus | ESCC | 1.98e-10 | 3.12e-01 | 0.1131 |
| 10450 | PPIE | P10T-E | Human | Esophagus | ESCC | 7.25e-72 | 1.24e+00 | 0.116 |
| 10450 | PPIE | P11T-E | Human | Esophagus | ESCC | 4.63e-14 | 6.29e-01 | 0.1426 |
| 10450 | PPIE | P12T-E | Human | Esophagus | ESCC | 2.14e-23 | 4.20e-01 | 0.1122 |
| 10450 | PPIE | P15T-E | Human | Esophagus | ESCC | 9.58e-32 | 6.11e-01 | 0.1149 |
| 10450 | PPIE | P16T-E | Human | Esophagus | ESCC | 3.55e-21 | 4.97e-01 | 0.1153 |
| 10450 | PPIE | P17T-E | Human | Esophagus | ESCC | 9.43e-12 | 6.52e-01 | 0.1278 |
| 10450 | PPIE | P19T-E | Human | Esophagus | ESCC | 9.00e-11 | 9.01e-01 | 0.1662 |
| 10450 | PPIE | P20T-E | Human | Esophagus | ESCC | 7.61e-24 | 5.75e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:0019079111 | Esophagus | ESCC | viral genome replication | 102/8552 | 131/18723 | 4.31e-14 | 2.19e-12 | 102 |
| GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
| GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
| GO:0045069110 | Esophagus | ESCC | regulation of viral genome replication | 67/8552 | 85/18723 | 3.81e-10 | 1.04e-08 | 67 |
| GO:0048524110 | Esophagus | ESCC | positive regulation of viral process | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
| GO:004507015 | Esophagus | ESCC | positive regulation of viral genome replication | 24/8552 | 30/18723 | 1.27e-04 | 8.67e-04 | 24 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:001603212 | Liver | Cirrhotic | viral process | 203/4634 | 415/18723 | 5.40e-27 | 3.76e-24 | 203 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPIE | SNV | Missense_Mutation | c.41C>T | p.Ala14Val | p.A14V | Q9UNP9 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PPIE | SNV | Missense_Mutation | rs747872958 | c.686N>T | p.Thr229Met | p.T229M | Q9UNP9 | protein_coding | tolerated(0.07) | possibly_damaging(0.476) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
| PPIE | SNV | Missense_Mutation | novel | c.421N>G | p.Gln141Glu | p.Q141E | Q9UNP9 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| PPIE | SNV | Missense_Mutation | c.232C>T | p.Arg78Cys | p.R78C | Q9UNP9 | protein_coding | deleterious(0.04) | benign(0.097) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPIE | SNV | Missense_Mutation | rs764879686 | c.326N>T | p.Thr109Met | p.T109M | Q9UNP9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.911) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| PPIE | SNV | Missense_Mutation | novel | c.53N>G | p.Asp18Gly | p.D18G | Q9UNP9 | protein_coding | deleterious(0.02) | probably_damaging(0.914) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| PPIE | SNV | Missense_Mutation | rs747872958 | c.686N>T | p.Thr229Met | p.T229M | Q9UNP9 | protein_coding | tolerated(0.07) | possibly_damaging(0.476) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPIE | SNV | Missense_Mutation | rs149451835 | c.410N>A | p.Arg137His | p.R137H | Q9UNP9 | protein_coding | tolerated(0.06) | benign(0.434) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPIE | SNV | Missense_Mutation | rs764879686 | c.326N>T | p.Thr109Met | p.T109M | Q9UNP9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.911) | TCGA-D5-6534-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPIE | SNV | Missense_Mutation | c.673N>G | p.Ile225Val | p.I225V | Q9UNP9 | protein_coding | tolerated(0.37) | benign(0) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |